DUBLIN-(BUSINESS WIRE)–“Overactive Bladder (OAB) Treatment Market by Drug Type (Anticholinergics (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idiopathic OAB and Neurogenic OAB) and Region – Global Forecasts for 2027 ” Report added ResearchAndMarkets.com’s offering.
The global overactive bladder treatment market is projected to reach USD 4.2 billion by 2027 from USD 3.5 billion in 2022, at a CAGR of 3.6%
The rising prevalence of overactive bladder across the globe, along with increasing awareness of the treatment options available, is driving the growth of the market. In addition, the use of neuromodulation techniques to treat OAB is expected to have a significant positive impact.
Adoption of new treatments and launch of new drugs to treat OAB are also likely to support market growth in the coming years.
Mirabegron segment dominates the overactive bladder (OAB) treatment market in 2021.
On the basis of type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held the dominant market share in 2021, due to fewer side effects associated with this drug compared to other classes of drugs available in the market. Furthermore, the neuromodulation segment is expected to grow at a faster pace due to the launch of new SNM & PTNS for OAB in the market.
The idiopathic overactive bladder segment will witness the highest growth in the overactive bladder treatment market during the forecast period.
On the basis of disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment had a higher market share due to higher prevalence of idiopathic overactive bladder disorders and increased use of drugs for treatment.
North America had a dominant share in 2021.
In 2021, North America accounted for the largest share of the OAB treatment market. North America holds most of the key players in the market leading to the maturity of the OAB treatment market in this region. Moreover, the favorable reimbursement policy in the US is one of the leading factors predicting the growth of the market in North America.
The competitive landscape
Prominent players in this market are Astellas Pharma Inc. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (USA), Medtronic Plc (Ireland), AbbVie Inc. (USA), Viatris Inc. (USA) , Hisamitsu Pharmaceutical Co., Inc. (Japan), Johnson & Johnson Services, Inc. (USA) and Endo Pharmaceuticals Inc. (Ireland).
Market Dynamics
Market Drivers
-
Increasing prevalence of overactive bladder syndrome
-
The rapid aging of the population and the subsequent increase in the incidence of diseases characterized by Oab
-
Development and use of innovative intravesical therapies
-
Growing investment in research and development and the launch of new therapies in the coming years
Market restrictions
-
Frequent product recalls
-
Increased side effects of anticholinergic drugs
Market opportunities
-
New treatments, robust pipelines, and the patent cliff of certain drugs
Market challenges
-
Social stigma and lack of awareness about OAB
Mentioned companies:
-
Abbvie Inc
-
Ajanta Pharma
-
Altherk Pharmaceuticals
-
Amneal Pharmaceuticals LLC
-
Apotek Inc
-
Astellas Pharma Inc
-
Bayer Ag
-
Endo Pharmaceuticals Inc
-
Glenmark
-
Granules India Limited
-
Hisamitsu Pharmaceutical Co Inc
-
Hugel, Inc
-
Intas Pharmaceuticals Ltd
-
Johnson & Johnson Services, Inc
-
Laboratory
-
Lupine
-
Macleods Pharmaceuticals Ltd
-
Medtronic
-
Meditok
-
Pfizer Inc
-
Sun Pharmaceutical Industries Ltd
-
Taiho Pharmaceutical Co Ltd
-
Teva Pharmaceutical Industries Ltd
-
Urovant Sciences
-
Viatris Inc
For more information on this report, visit https://www.researchandmarkets.com/r/2n1a4i
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.
